Robledo-Cadena 2020 Pharmaceuticals (Basel): Difference between revisions
No edit summary |
No edit summary Β |
||
Line 8: | Line 8: | ||
|keywords=Bliss-type additivism model, HeLa cells, Celecoxib, Dimethylcelecoxib, Drug synergism, Resistance index | |keywords=Bliss-type additivism model, HeLa cells, Celecoxib, Dimethylcelecoxib, Drug synergism, Resistance index | ||
|editor=[[Plangger M]] | |editor=[[Plangger M]] | ||
|mipnetlab=MX Mexiko City Moreno-Sanchez R | |||
}} | }} | ||
{{Labeling | {{Labeling | ||
|area=Respiration | |area=Respiration, Pharmacology;toxicology | ||
|diseases=Cancer | |||
|organism=Human | |||
|tissues=Endothelial;epithelial;mesothelial cell, HeLa, Fibroblast | |||
|preparations=Intact cells | |||
|couplingstates=LEAK | |||
|instruments=Oxygraph-2k | |instruments=Oxygraph-2k | ||
|additional=2021-01 | |additional=2021-01 | ||
}} | }} |
Latest revision as of 20:20, 22 January 2021
Robledo-Cadena DX, Gallardo-PΓ©rez JC, DΓ‘vila-Borja V, Pacheco-VelΓ‘zquez SC, Belmont-DΓaz JA, Ralph SJ, Blanco-Carpintero BA, Moreno-SΓ‘nchez R, RodrΓguez-EnrΓquez S (2020) Non-steroidal anti-inflammatory drugs increase cisplatin, paclitaxel, and doxorubicin efficacy against human cervix cancer cells. Pharmaceuticals (Basel) 13:463. |
Robledo-Cadena Diana Xochiquetzal, Gallardo-Perez Juan Carlos, Davila-Borja Victor, Pacheco-Velazquez Silvia Cecilia, Belmont-Diaz Javier Alejandro, Ralph Stephen John, Blanco-Carpintero Betsy Alejandra, Moreno-Ssnchez Rafael, Rodriguez-Enriquez Sara (2020) Pharmaceuticals (Basel)
Abstract: This study shows that the non-steroidal anti-inflammatory drug (NSAID) celecoxib and its non-cyclooxygenase-2 (COX2) analogue dimethylcelecoxib (DMC) exert a potent inhibitory effect on the growth of human cervix HeLa multi-cellular tumor spheroids (MCTS) when added either at the beginning ("preventive protocol"; IC50 = 1 Β± 0.3 nM for celecoxib and 10 Β± 2 nM for DMC) or after spheroid formation ("curative protocol"; IC50 = 7.5 Β± 2 Β΅M for celecoxib and 32 Β± 10 Β΅M for DMC). These NSAID IC50 values were significantly lower than those attained in bidimensional HeLa cells (IC50 = 55 Β± 9 Β΅M celecoxib and 48 Β± 2 Β΅M DMC) and bidimensional non-cancer cell cultures (3T3 fibroblasts and MCF-10A mammary gland cells with IC50 from 69 to >100 Β΅M, after 24 h). The copper-based drug casiopeina II-gly showed similar potency against HeLa MCTS. Synergism analysis showed that celecoxib, DMC, and casiopeinaII-gly at sub-IC50 doses increased the potency of cisplatin, paclitaxel, and doxorubicin to hinder HeLa cell proliferation through a significant abolishment of oxidative phosphorylation in bidimensional cultures, with no apparent effect on non-cancer cells (therapeutic index >3.6). Similar results were attained with bidimensional human cervix cancer SiHa and human glioblastoma U373 cell cultures. In HeLa MCTS, celecoxib, DMC and casiopeina II-gly increased cisplatin toxicity by 41-85%. These observations indicated that celecoxib and DMC used as adjuvant therapy in combination with canonical anti-cancer drugs may provide more effective alternatives for cancer treatment. β’ Keywords: Bliss-type additivism model, HeLa cells, Celecoxib, Dimethylcelecoxib, Drug synergism, Resistance index β’ Bioblast editor: Plangger M β’ O2k-Network Lab: MX Mexiko City Moreno-Sanchez R
Labels: MiParea: Respiration, Pharmacology;toxicology
Pathology: Cancer
Organism: Human Tissue;cell: Endothelial;epithelial;mesothelial cell, HeLa, Fibroblast Preparation: Intact cells
Coupling state: LEAK
HRR: Oxygraph-2k
2021-01